港股異動 | 綠城中國(3900.HK)漲4.1% 股東應占利潤44.69億元 同比增長17.7%
格隆匯3月23日丨綠城中國(3900.HK)漲4.1%,報12.7港元,總市值317億港元。該公司昨日發佈業績報吿,2021年公司營業收入1002.40億元,同比增長52.38%;股東應占利潤44.69億元,同比增長17.7%。基本每股收益為1.31元。年報顯示,2021年,公司實現合同銷售面積約1557萬平方米,合同銷售金額3509億元,同比增長21%,完成全年目標的113%。公司還預計,2022年,公司整體可售貨源約2034萬平方米,可售金額約4442億元;其中,自投項目可售貨源約1354萬平方米,可售金額約3452億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.